HMGB1 and Sepsis: Notably, these anti-HMGB1 reagents are capable of rescuing mice from lethal experimental sepsis even when the first doses are given 24 h after the onset of the disease [11]–[13], [21], [23], indicating a wider window for HMGB1-targeted therapeutic strategies.